Salmeterol/fluticasone combination in the treatment of COPD

References

• AdcockIMChungKF2002Why are corticosteroids ineffective in COPD?Curr Opin Investig Drugs35860
   Google Scholar
• AlsaeediASinDDMcAlisterFA2002The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trialsAm J Med113596512106623
   PubMed Web of Science ®Google Scholar
• AppletonSSmithBVealeA2000Long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev2CD00110410796594
   PubMedGoogle Scholar
• BarnesNCQiuY-SPavordI2006Anti-inflammatory effects of sameterol/fluticasone propionate in chronic obstructive lung diseaseAmer J Respir Crit Care Med 2006173736743
   PubMed Web of Science ®Google Scholar
• BourbeauJRouleauMYBoucherS1998Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary diseaseThorax53477829713447
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMJonesPW2000Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBr Med J320129730310807619
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJ2003aCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet3614495612583942
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZ2003bMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J229121914680078
   PubMed Web of Science ®Google Scholar
• CazzolaMSantusPDi MarcoF2003Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPDRespir Med97453712735659
   PubMed Web of Science ®Google Scholar
• CelliBRCoteCGMarinJM2004The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med35010051214999112
   PubMed Web of Science ®Google Scholar
• ConfalonieriMMainardiEDellaPR1998Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease [see comments]Thorax5358359797758
   PubMed Web of Science ®Google Scholar
• CulpittSVMaziakWLoukidisS1999Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1601635910556133
   PubMed Web of Science ®Google Scholar
• Dal NegroRWPomariCTognellaS2003Salmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophyllinePulm Pharmacol Ther16241612850128
   PubMed Web of Science ®Google Scholar
• DonohueJFKalbergCEmmettA2004A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPDTreat Respir Med31738115219176
   PubMedGoogle Scholar
• DonohueJFOharJA2004Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary diseaseProc Am Thorac Soc11526016113428
   PubMedGoogle Scholar
• EickelbergORothMLorxR1999Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cellsJ Biol Chem2741005109873044
   PubMed Web of Science ®Google Scholar
• GizyckiMJHattotuwaKLBarnesN2002Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissueThorax5779980312200525
   PubMed Web of Science ®Google Scholar
• HalpinDM2005Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysisInt J Clin Pract5911879416178987
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanD2003The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest1248344312970006
   PubMed Web of Science ®Google Scholar
• HattotuwaKLGizyckiMJAnsariTW2002The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy studyAm J Respir Crit Care Med1651592612070058
   PubMed Web of Science ®Google Scholar
• ItoKChungKFAdcockIM2006Update on glucocorticoid actions and resistanceJ Allergy Clin Immunol11752254316522450
   PubMed Web of Science ®Google Scholar
• JarvisBMarkhamA2001Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary diseaseDrugs Aging184417211419918
   PubMed Web of Science ®Google Scholar
• JohnsonM2005Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary diseaseProc Am Thorac Soc2320516267356
   PubMedGoogle Scholar
• Lung Health Study Research Group2000Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med3431902911136260
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanD2002Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med16610849112379552
   PubMed Web of Science ®Google Scholar
• MakeBHananiaNAZuWallackR2005The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group studyClin Ther275314215978302
   PubMed Web of Science ®Google Scholar
• NanniniLCatesCJLassersonTJ2004Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary diseaseCochrane Database Syst Rev3CD00379415266502
   PubMedGoogle Scholar
• PauwelsRALofdahlCGLaitinenLA1999Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease [see comments]N Engl J Med34019485310379018
   PubMed Web of Science ®Google Scholar
• RothMJohnsonPRRudigerJJ2002Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signallingLancet3601293912414205
   PubMed Web of Science ®Google Scholar
• SinDDLacyPYorkE2004Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med170760515229100
   PubMed Web of Science ®Google Scholar
• SinDDManPMarciniukDD2006Can Inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [clinicaltrials.gov NCT120978]BMC Pulm Med6316460562
   PubMedGoogle Scholar
• SinDDMcAlisterFAManSF2003Contemporary management of chronic obstructive pulmonary disease: scientific reviewJAMA29023011214600189
   PubMed Web of Science ®Google Scholar
• SinDDTuJV2001Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med164580411520719
   PubMed Web of Science ®Google Scholar
• SinDDWuLAndersonJA2005Inhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax60992716227327
   PubMed Web of Science ®Google Scholar
• SorianoJBKiriVAPrideNB2003Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patientsAm J Respir Med2677414720023
   PubMedGoogle Scholar
• SorianoJBVestboJPrideNB2002Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practiceEur Respir J208192512412670
   PubMed Web of Science ®Google Scholar
• SuissaS2004Inhaled steroids and mortality in COPD: bias from unaccounted immortal timeEur Respir J23391515065827
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
   PubMed Web of Science ®Google Scholar
• TerzanoCPetroianniARicciA2005Combination therapy in COPD: different response of COPD stages and predictivity of functional parametersEur Rev Med Pharmacol Sci92091516128040
   PubMedGoogle Scholar
• van der ValkPMonninkhofEvan der PalenJ2002Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med16613586312406823
   PubMed Web of Science ®Google Scholar
• VestboJ2004The TORCH (towards a revolution in COPD health) survival study protocolEur Respir J242061015332386
   PubMed Web of Science ®Google Scholar
• VestboJPauwelsRAndersonJA2005Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary diseaseThorax60301415790985
   PubMed Web of Science ®Google Scholar
• VestboJSorensenTLangeP1999Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet35318192310359405
   PubMed Web of Science ®Google Scholar
• VestboJSorianoJBAndersonJA2004Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPDRespir Med9810455015526804
   PubMed Web of Science ®Google Scholar
• WoutersEFPostmaDSFokkensB2005Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax60480715923248
   PubMed Web of Science ®Google Scholar